Stock comparison
Royalty Pharma
Vericel
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
RPRX
Royalty Pharma
Market cap
$23.44B
Sector
Healthcare
VCEL
Vericel
Market cap
$1.77B
Sector
Healthcare
Overall winner
Royalty Pharma RPRX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | RPRX | VCEL | Winner |
|---|---|---|---|
| Warren Buffett | 66C | 52D | RPRX |
| Benjamin Graham | 84A | 69D | RPRX |
| Philip Fisher | 65C | 57C | RPRX |
| Peter Lynch | 60C | 45D | RPRX |
| Joel Greenblatt | 40D | 44D | VCEL |
| Charlie Munger | 68D | 43D | RPRX |
| Terry Smith | 58D | 52D | RPRX |
Side-by-side metrics
| Metric | RPRX | VCEL |
|---|---|---|
| Market cap | $23.44B | $1.77B |
| P/E (TTM) | 27.6x | 82.5x |
| EV/EBIT | 19.9x | 159.9x |
| ROIC (TTM) | 8.43% | 3.35% |
| Gross margin | 99.95% | 74.84% |
| Net margin | 33.91% | 7.35% |
| Revenue CAGR 5y | 0.96% | 15.32% |
| EPS CAGR 5y | 11.83% | - |
| Debt / Equity | 1.3x | 0.3x |
| Dividend yield | 1.72% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
RPRX leads on
- Dividend yield1.72%vs 0.0%+100%
- Market cap$23.44Bvs $1.77B+92%
- EV/EBIT19.9xvs 159.9x+88%
- Net margin33.91%vs 7.35%+78%
VCEL leads on
- Revenue CAGR 5y15.32%vs 0.96%+94%
- Debt / Equity0.3xvs 1.3x+80%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.